S. P. J. Whelan

This paper shows LCMV spreads between cells via tunnelling nanotube-like structures, bypassing extracellular transmission.

This study identifies potassium ion flux as a third requirement for LCMV entry, showing it facilitates uncoating by modulating NP/Z interactions.

This study shows that SARS-CoV-2 boosting induces GC B cell responses and that Omicron-based vaccines can elicit novel epitope-specific antibodies despite antigenic imprinting.

This study shows SARS-CoV-2 requires acidic pH for membrane fusion and genome release, even after proteolytic cleavage by furin or TMPRSS2.

This study identifies Lrp1 as a host factor required for Oropouche orthobunyavirus infection and suggests a broader role for Lrp1 in bunyavirus entry.

This study shows FXa cleaves SARS-CoV-2 spike protein, blocking viral entry, but B.1.1.7 variant is resistant, and FXa inhibitors like rivaroxaban reduce this protection.

This study shows SARS-CoV-2 spreads through cell-to-cell contact via spike glycoprotein, which is more efficient than SARS-CoV and resistant to neutralizing antibodies.

This paper identifies a novel class of TMPRSS2 inhibitors that effectively block SARS-CoV-2 and MERS-CoV entry and show promise as a therapeutic for COVID-19.

The paper identifies an antibody that neutralizes all SARS-CoV-2 variants by targeting a conserved epitope on the spike protein.

This paper identifies a human monoclonal antibody that broadly neutralizes SARS-CoV-2 variants and zoonotic sarbecoviruses by targeting a conserved epitope on the spike protein.

A vaccine-induced human monoclonal antibody neutralizes SARS-CoV-2 and variants, reducing lung inflammation and viral load in hamsters.

This study identifies H522 cells as ACE2-negative human cells permissive to SARS-CoV-2 infection, revealing alternative receptor usage and host response mechanisms.

This paper develops a chimeric VSV expressing OROV glycoproteins that elicits neutralizing antibodies and reduces viral infection in mice.

This paper describes a fully human immunoglobulin from transchromosomic bovines that neutralizes SARS-CoV-2 variants, including those with mutations like E484K and N501Y.

This study identifies PCIF1's role in attenuating the antiviral effects of interferon-β by modifying VSV mRNA caps, enhancing viral evasion of innate immunity.

The paper identifies CH25H and its product 25HC as inhibitors of SARS-CoV-2 replication by blocking membrane fusion.

The paper identifies JIB-04 as a broad-spectrum antiviral that inhibits SARS-CoV-2 replication and coronavirus pathogenesis in vitro and in vivo.

This study develops two neutralization assays for SARS-CoV-2 using VSV and a clinical isolate, showing high concordance between monoclonal, polyclonal antibodies, and ACE2-Fc in neutralizing activity.

The paper identifies EnvP(b)1, an ancient retroviral envelope gene expressed in human tissues, and shows its structural similarity to modern leukemia virus Envs, suggesting a conserved scaffold for receptor binding evolution.

This study shows SARS-CoV-2 infects human intestinal enterocytes via TMPRSS2 and TMPRSS4, but viral particles in stool are inactivated, suggesting limited fecal-oral transmission.

The paper shows that PIKfyve kinase inhibitors block infection by Zaire ebolavirus and SARS-CoV-2 by preventing viral content release.

This study identifies heparan sulfate as critical for HERV-K virus entry and defines key steps in its infectious pathway.